Tamminga C A, Chase T N
Arch Neurol. 1980 Apr;37(4):204-5. doi: 10.1001/archneur.1980.00500530042004.
Dopamine agonist therapy using selected drugs at particular dosage levels has been found to have therapeutic benefit in certain dyskinetic syndromes. Two ergot derivatives with dopamine agonist properties were administered at relatively low doses to eight neuroleptic-free schizophrenic patients with tardive dyskinesia. Neither agent significantly improved dyskinetic symptoms; no symptoms worsened. Dopamine agonists likely vary in their selective activation of functionally distinct dopamine receptors.
已发现使用特定剂量的选定药物进行多巴胺激动剂治疗在某些运动障碍综合征中具有治疗益处。对8名无抗精神病药物的迟发性运动障碍精神分裂症患者给予两种具有多巴胺激动剂特性的麦角衍生物，剂量相对较低。两种药物均未显著改善运动障碍症状；也没有症状恶化。多巴胺激动剂对功能不同的多巴胺受体的选择性激活可能存在差异。
